We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.91%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$196M
Cap. Flow
+$54.1M
Cap. Flow %
4.71%
Top 10 Hldgs %
49.21%
Holding
84
New
12
Increased
28
Reduced
17
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.9M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$38.9M
3
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$18M
4
KND
Kindred Healthcare
KND
+$12.2M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$12.1M

Top Sells

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$33.9M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$19.1M
3
IPXL
Impax Laboratories, Inc.
IPXL
+$15.6M
4
NTUS
Natus Medical Inc
NTUS
+$13.7M
5
CEMP
Cempra, Inc.
CEMP
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 83.26%
2 Consumer Discretionary 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRS
26
DELISTED
Antares Pharma, Inc.
ATRS
$12.1M 1.05%
4,700,000
+1,000,000
+27% +$2.25M
SLXP
27
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$11.5M 1%
+100,000
New +$12.1M
CARM
28
DELISTED
Carisma Therapeutics
CARM
$11.5M 1%
48,331
+5,445
+13% +$1.22M
CNMD icon
29
CONMED
CNMD
$1.29B
$11.2M 0.98%
250,000
+100,000
+67% +$4.19M
CORI
30
DELISTED
Corium International, Inc.
CORI
$10.6M 0.92%
1,736,736
+336,736
+24% +$1.91M
LGND icon
31
Ligand Pharmaceuticals
LGND
$6.02B
$10.6M 0.92%
+318,997
New +$10.4M
ELOS
32
DELISTED
Syneron Medical Ltd
ELOS
$9.38M 0.82%
1,005,221
– –
WINT
33
DELISTED
Windtree Therapeutics Inc
WINT
$9.36M 0.81%
576,143
– –
TLGT
34
DELISTED
Teligent, Inc
TLGT
$8.58M 0.75%
97,481
-16,000
-14% -$1.5M
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$8.55M 0.74%
779,706
+75,000
+11% +$743K
TRVN
36
DELISTED
Trevena, Inc.
TRVN
$8.43M 0.73%
2,255
+1,295
+135% +$4.29M
XNCR icon
37
Xencor
XNCR
$1.44B
$8.36M 0.73%
520,881
-232,802
-31% -$2.7M
FLXN
38
DELISTED
Flexion Therapeutics, Inc.
FLXN
$8.34M 0.73%
413,204
+200,000
+94% +$3.62M
PRTK
39
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.03M 0.7%
+260,283
New +$6.21M
INFI
40
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.6M 0.66%
450,000
-404,384
-47% -$5.89M
TENX icon
41
Tenax Therapeutics
TENX
$385M
$7.56M 0.66%
62
– –
CPRX
42
DELISTED
Catalyst Pharmaceutical
CPRX
$7.13M 0.62%
2,400,000
+1,000,000
+71% +$2.74M
CEMP
43
DELISTED
Cempra, Inc.
CEMP
$6.69M 0.58%
284,625
-670,522
-70% -$10M
CRDC
44
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$6.21M 0.54%
887,499
+100
+0% +$823
ADYX
45
DELISTED
Adynxx Inc
ADYX
$6.21M 0.54%
19,515
-6,240
-24% -$1.71M
VXRT
46
DELISTED
Vaxart
VXRT
$5.85M 0.51%
237,428
– –
PLXP
47
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$5.41M 0.47%
59,375
– –
ARAY icon
48
Accuray
ARAY
$28.4M
$5.29M 0.46%
700,000
+200,000
+40% +$1.41M
ASPX
49
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$5.25M 0.46%
+100,000
New +$2.94M
GNMX
50
DELISTED
Aevi Genomic Medicine Inc
GNMX
$5.19M 0.45%
+1,025,000
New +$5.06M
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Broadfin Capital held 84 positions worth $1.15B, up 21% from $954M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Broadfin Capital deployed $54.1M of net new capital in Q4 2014, opening 12 new positions and adding to 28 existing holdings. Its largest new stake was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the largest reduction was AMAG Pharmaceuticals, an estimated $33.9M trimmed.

  • Broadfin Capital's largest Q4 2014 buy was SALIX PHARMACEUTICALS LTD DEL: 100,000 shares worth $11.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014, an estimated $47.9M increase.
  • Broadfin Capital's biggest Q4 2014 reduction was AMAG Pharmaceuticals, cutting an estimated $33.9M.
  • Broadfin Capital fully exited Tetraphase Pharmaceuticals, Inc. in Q4 2014, selling an estimated $19.1M.
  • Broadfin Capital's ten largest holdings make up 49% of its $1.15B portfolio in Q4 2014.
  • Broadfin Capital opened 12 new positions and closed 9 in Q4 2014.
  • Broadfin Capital's portfolio value rose 21% quarter-over-quarter to $1.15B.

Based on Broadfin Capital's 13F filing for Q4 2014, filed 17 Feb 2015.